# US 8,785,474 B2 · Vanilloid receptor ligands, pharmaceutical compositions containing them, process for making them, and use thereof to treat pain and other conditions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,785,474 B2
- Document ID: US8785474B2
- Status: Granted
- Kind: B2
- Application number: 13/210,719
- Filed: 2011-08-16
- Published: 2011-12-08
- Granted: 2014-07-22
- Earliest claimed: 2007-04-16
- Assignees: Gruenenthal GmbH
- Applicants: Robert Frank; Gregor Bahrenberg; Thomas Christoph; Klaus Schiene; Jean De Vry; Derek Saunders; Bernd Sundermann; Jeewoo Lee
- Inventors: Robert Frank; Gregor Bahrenberg; Thomas Christoph; Klaus Schiene; Jean De Vry; Derek Saunders; Bernd Sundermann; Jeewoo Lee
- Web page: https://patentgrep.com/patent/US8785474B2

## CPC

- C07D 235/24: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/12: Antidiarrhoeals
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 13/00: Drugs for disorders of the urinary system
- A61P 13/10: of the bladder
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/04: Antipruritics
- A61P 17/06: Antipsoriatics
- A61P 19/10: for osteoporosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/06: Antimigraine agents
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/30: for treating abuse or dependence
- A61P 25/32: Alcohol-abuse
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07D 241/40: Benzopyrazines
- C07D 263/54: Benzoxazoles; Hydrogenated benzoxazoles
- C07D 265/36: condensed with one six-membered ring
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Vanilloid receptor ligand compounds corresponding to formula I: pharmaceutical compositions containing such compounds, a process for producing such compounds, and methods of using such compounds for treating or inhibiting pain and various other disorders or conditions.

## Claims

### Claim 1

A compound corresponding to formula I:
wherein
n is 0, 1, 2, 3 or 4;
R1 and R2 together denote —CH═CH—N═CH—, which is attached in any desired direction to the parent structure; or
R2 and R3 together denote a residue selected from the group consisting of —CH═CH—CH═N—; —CH═CH—N═CH—; —CR68═CR69—CH═N—; and —CR68═CR69—N═CR70—, which is attached in any desired direction to the parent structure; or
R3 and R4 together denote a residue selected from the group consisting of —CH═CH—CH═N—; —CH═CH—N═CH—; —CR68═CR69—CH═N—; and —CR68═CR69—N═CR70—, which is attached in any desired direction to the parent structure; or
R4 and R5 together denote —CH═CH—N═CH—, which is attached in any desired direction to the parent structure; and
the remaining residues of R1, R2, R3, R4 and R5 each independently represent H; F; Cl; Br; I; —SF5; —NO2; —CN; —NH2; —OH; —SH; —C(═O)—NH2; —S(═O)2—NH2; —C(═O)—NH—OH; —C(═O)—OH; —C(═O)—H; —S(═O)2—OH; —C(═NH)—NH2; —C(═NH)—NH—R9; —N═C(NH2)2; —N═C(NHR10)(NHR11); —O—P(═O)2—O—R12; —NHR13; —NR14R15; —NH—C(═O)—R13; —OR16; —SR17; —C(═O)—NHR18; —C(═O)—NR19R20; —S(═O)2—NHR21; —S(═O)2—NR22R23; —C(═O)—OR24; —C(═O)—R25; —S(═O)—R26; —S(═O)2—R27 or a linear or branched, saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted aliphatic C1-10 residue;
R6 denotes H or a linear or branched, saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted aliphatic C1-10 residue;
R7 denotes hydrogen or —OH; or
R6 and R7 together with the carbon atom to which they are attached form a saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted 3-, 4-, 5-, 6- or 7-membered cycloaliphatic residue;
R8 denotes —SF5; —O—CF3; —CF3; —O—CFH2; —O—CF2H; —CFH2; —CF2H; or an unsubstituted, monosubstituted or polysubstituted tert.-butyl residue;
T denotes C—R35; U denotes C—R36; V denotes N, and W denotes C—R38; or
T denotes C—R35; U denotes N; V denotes C—R37, and W denotes C—R38; or
T denotes N; U denotes C—R36; V denotes C—R37, and W denotes C—R38; or
T denotes N; U denotes N; V denotes C—R37, and W denotes C—R38; or
T denotes N; U denotes C—R36; V denotes N, and W denotes C—R38; or
T denotes C—R35; U denotes N; V denotes N, and W denotes C—R38; or
T denotes C—R35; U denotes C—R36; V denotes C—R37, and W denotes C—R38;
R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, R25, R26 and R27 each independently denote a linear or branched, saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted aliphatic C1-10 residue; or
an unsaturated or saturated, unsubstituted, monosubstituted or polysubstituted 3-, 4-, 5-, 6-, 7-, 8- or 9-membered cycloaliphatic residue optionally comprising at least one heteroatom as a ring member, wherein said cycloaliphatic residue optionally may be fused with a saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted mono- or polycyclic ring system, or optionally may be attached via a linear or branched, unsubstituted, monosubstituted or polysubstituted C1-6 alkylene group or 2- to 6-membered heteroalkylene group, or both; or
an unsubstituted, monosubstituted or polysubstituted 5- to 14-membered aryl or heteroaryl residue, which optionally may be fused with a saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted mono- or polycyclic ring system, or optionally may be attached via a linear or branched, unsubstituted, monosubstituted or polysubstituted C1-6 alkylene group or 2- to 6-membered heteroalkylene group, or both;
R35, R36 and R37 each independently denote H; F; Cl; Br; I; —SF5; —NO2; —CF3; —CN; —NH2; —OH; —SH; —C(═O)—NH2; —S(═O)2—NH2; —C(═O)—NH—OH; —C(═O)—OH; —C(═O)—H; —S(═O)2—OH; —NHR13; —NR14R15; —NH—C(═O)—R13; —OR16; —SR17; —C(═O)—NHR18; —C(═O)—NR19R20; —S(═O)2—NHR21; —S(═O)2—NR22R23; —C(═O)—OR24; —C(═O)—R25; —S(═O)—R26; —S(═O)2—R27; or a linear or branched, saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted aliphatic C1-10 residue; or
an unsubstituted, monosubstituted or polysubstituted 5- to 14-membered aryl or heteroaryl residue, which optionally may be fused with a saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted mono- or polycyclic ring system, or optionally may be attached via a linear or branched, unsubstituted, monosubstituted or polysubstituted C1-6 alkylene group or C2-6 alkenylene group or C2-6 alkynylene group, or both;
R38 denotes —NR40R41; —OR42; or —SR43;
R40, R41, R42, and R43 each independently denote a linear or branched, saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted aliphatic C1-10 residue; or
an unsaturated or saturated, unsubstituted, monosubstituted or polysubstituted 3-, 4-, 5-, 6-, 7-, 8- or 9-membered cycloaliphatic residue optionally comprising one or more heteroatom(s) as ring member(s), wherein said cycloaliphatic residue optionally be fused with a saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted mono- or polycyclic ring system, or optionally may be attached via a linear or branched, unsubstituted, monosubstituted or polysubstituted C1-6 alkylene group or 2- to 6-membered heteroalkylene group, or both; or
an unsubstituted, monosubstituted or polysubstituted 5- to 14-membered aryl or heteroaryl residue, which optionally may be fused with a saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted mono- or polycyclic ring system, or optionally may be attached via a linear or branched, unsubstituted, monosubstituted or polysubstituted C1-6 alkylene group or 2- to 6-membered heteroalkylene group, or both; or
R40 and R41 together with the nitrogen atom to which they are attached form a saturated or unsaturated or unsubstituted heterocycloaliphatic residue or a 4-, 5-, 6-, 7-, 8- or 9-membered heterocycloaliphatic residue substituted with 1, 2, 3, 4 or 5 residues R57 and optionally comprising one or more further heteroatom(s) as ring member(s), wherein said heterocycloaliphatic residue optionally may be fused with a saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted mono- or polycyclic ring system;
R57 denotes —NHR58, —NR59R60; or a linear or branched, saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted aliphatic C1-10 residue;
R58, R59 and R60 each independently denote —C(═O)—R61; or a linear or branched, saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted aliphatic C1-10 residue; or an unsubstituted, monosubstituted or polysubstituted 5- to 14-membered aryl or heteroaryl residue, which optionally may be fused with a saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted mono- or polycyclic ring system, or optionally may be attached via a linear or branched, unsubstituted, monosubstituted or polysubstituted C1-6 alkylene group or C2-6 alkenylene group or C2-6 alkynylene group, or both;
R61 denotes a linear or branched, saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted aliphatic C1-10 residue; and
R68, R69 and R70 each independently denote F, Cl, Br, I, or a linear or branched, saturated or unsaturated, unsubstituted, monosubstituted or polysubstituted aliphatic C1-10 residue;
or a salt thereof;
wherein:
said aliphatic C1-10 residues and tert.-butyl residues each optionally may be substituted with 1, 2, 3, 4, 5, 6, 7, 8 or 9 substituents independently selected from the group consisting of F, Cl, Br, I, —CN, —NO2, —OH, —NH2, —SH, —O(C1-5-alkyl), —S(C1-5-alkyl), —NH(C1-5-alkyl), —N(C1-5-alkyl)(C1-5-alkyl), —C(═O)—O—C1-5-alkyl, —O—C(═O)—C1-5-alkyl, —O-phenyl, phenyl, —OCF3 and —SCF3;
said 2- to 6-membered heteroalkylene groups, C1-6 alkylene groups, C2-6 alkenylene groups and C2-6 alkynylene groups each optionally may be substituted with 1, 2, 3, 4, 5, 6, 7, 8 or 9 substituents independently selected from the group consisting of F, Cl, Br, I, —CN, —NO2, —OH, —NH2, —SH, —O(C1-5-alkyl), —S(C1-5-alkyl), —NH(C1-5-alkyl), —N(C1-5-alkyl)(C1-5-alkyl), —OCF3 and —SCF3;
said heteroalkylene groups each optionally may comprise 1, 2 or 3 heteroatom(s) independently selected from the group consisting of oxygen, nitrogen as NH, and sulfur as chain link(s);
said (hetero)cycloaliphatic residues each optionally may be substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of —C1-6-alkylene-OH, ═CH2, —O—C1-5-alkylene-oxetanyl, —C1-5-alkylene-O—C1-5-alkylene-oxetanyl, —CH2—NH—C1-5-alkyl, —CH2—N(C1-5-alkyl)2, —N[—C(═O)—C1-5-alkyl]-phenyl, —CH2—O—C1-5-alkyl, oxo (═O), thioxo (═S), F, Cl, Br, I, —CN, —CF3, —SF5, —OH, —O—C1-5-alkyl, —O—C(═O)—C1-5-alkyl, —NH2, —NO2, —O—CF3, —S—CF3, —SH, —S—C1-5-alkyl, —C1-5-alkyl, —C(═O)—C1-5-alkyl, —C(═O)—OH, —C(═O)—O—C1-5-alkyl, —NH—C1-5-alkyl, —N(C1-5-alkyl)2, —NH-phenyl, —N(—C1-5-alkyl)-phenyl, cyclohexyl, cyclopentyl, (4,5)-dihydroisoxazolyl, thiazolyl, (1,2,5)-thiadiazolyl, thiophenyl, phenethyl, piperidinyl, pyrrolidinyl, —(CH2)-pyridinyl, pyridinyl, —O-phenyl, —O-benzyl, phenyl and benzyl, wherein the cyclic moiety of the oxetanyl, (4,5)-dihydroisoxazolyl, thiazolyl, (1,2,5)-thiadiazolyl, thiophenyl, phenethyl, —N[—C(═O)—C1-5-alkyl]-phenyl, —NH-phenyl, —N(—C1-5-alkyl)-phenyl, —(CH2)-pyridinyl, pyridinyl, —O-phenyl, —O-benzyl, phenyl and benzyl residues optionally may be substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, —OH, —CF3, —SF5, —CN, —NO2, —C1-5 alkyl, —O—C1-5-alkyl, —O—CF3, —S—CF3, phenyl and —O-benzyl;
unless otherwise stated, said (hetero)cycloaliphatic residues each optionally may comprise 1, 2 or 3 (further) heteroatom(s) independently selected from the group consisting of oxygen, nitrogen and sulfur;
the rings of said mono- or polycyclic ring systems each optionally may be substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of oxo (═O), thioxo (═S),), F, Cl, Br, I, —CN, —CF3, —SF5, —OH, —O—C1-5-alkyl, —NH2, —NO2, —O—CF3, —S—CF3, —SH, —S—C1-5-alkyl, —C1-5-alkyl, —C(═O)—C1-5-alkyl, —C(═O)—OH, —C(═O)—O—C1-5-alkyl, —NH—C1-5-alkyl, —N(C1-5-alkyl)2, —O-phenyl, —O-benzyl, phenyl and benzyl, wherein the cyclic moiety of the —O-phenyl, —O-benzyl, phenyl and benzyl residues optionally may be substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, —OH, —CF3, —SF5, —CN, —NO2, —C1-5 alkyl, —O—C1-5-alkyl, —O—CF3, —S—CF3, phenyl and —O-benzyl;
the rings of said mono- or polycyclic ring systems each are 5-, 6- or 7-membered and optionally may comprise 1, 2, 3, 4 or 5 heteroatom(s) as ring member(s), which are independently selected from the group consisting of oxygen, nitrogen and sulfur;
said aryl or heteroaryl residues each optionally may be substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, I, —CN, —CF3, —SF5, —OH, —O—C1-5-alkyl, —NH2, —NO2, —O—CF3, —S—CF3, —SH, —S—C1-5-alkyl, —C1-5-alkyl, —C(═O)—OH, —C(═O)—C1-5-alkyl, —NH—C1-5-alkyl, —N(C1-5-alkyl)2, —NH—S(═O)2—C1-5-alkyl, —NH—C(═O)—O—C1-5-alkyl, —C(═O)—H, —C(═O)—C1-5-alkyl, —C(═O)—NH2, —C(═O)—NH—C1-5-alkyl, —C(═O)—N—(C1-5-alkyl)2, —O-phenyl, —O-benzyl, phenyl and benzyl, wherein the cyclic moiety of the —O-phenyl, —O-benzyl, phenyl and benzyl residues optionally may be substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, —OH, —CF3, —SF5, —CN, —NO2, —C1-5 alkyl, —O—C1-5-alkyl, —O—CF3, —S—CF3, phenyl and —O-benzyl; and
said heteroaryl residues each optionally may comprise 1, 2, 3, 4 or 5 heteroatom(s) independently selected from the group consisting of oxygen, nitrogen and sulfur as ring member(s).

### Claim 2 (depends on 1)

A compound according to claim 1, wherein said compound is present in the form of an isolated stereoisomer.

### Claim 3 (depends on 1)

A compound according to claim 1, wherein said compound is present in the form of a mixture of stereoisomers in any mixing ratio.

### Claim 4 (depends on 1)

A compound according to claim 1, wherein said compound is present in the form of a racemic mixture.

### Claim 5 (depends on 1)

A compound according to claim 1, wherein:
n is 0, 1, 2, 3 or 4;
R1 and R2 together denote —CH═CH—N═CH—, which is attached in any desired direction to the parent structure; or
R2 and R3 together denote a residue selected from the group consisting of —CH═CH—CH═N— and —CH═CH—N═CH—, which is attached in any desired direction to the parent structure; or
R3 and R4 together denote a residue selected from the group consisting of —CH═CH—CH═N— and —CH═CH—N═CH—, which is attached in any desired direction to the parent structure; or
R4 and R5 together denote —CH═CH—N═CH—, which is attached in any desired direction to the parent structure; and
the remaining residues of R1, R2, R3, R4 and R5 each independently denote H; F; Cl; Br; I; —SF5; —NO2; —CN; —NH2; —OH; —SH; —C(═O)—NH2; —S(═O)2—NH2; —C(═O)—NH—OH; —C(═O)—OH; —C(═O)—H; —S(═O)2—OH; —NHR13; —NR14R15; —NH—C(═O)—R13; —OR16; —SR17; —S(═O)—R26; —S(═O)2—R27; methyl, —CF3, —CCl3, —CBr3, —CHF2, —CH2F, —CF2Cl, —CCl2F, ethyl, —CF2—CH3, —CH2—CF3, —C2F5, —CH2—CCl3, —CH2—CBr3, —CHF—CF2Cl, —CF2—CF2Cl, —CFCl—CF2Cl, n-propyl, —CF2—CF2—CF3, —CF(CF3)2, isopropyl, n-butyl, sec.-butyl, isobutyl, or tert.-butyl;
R6 denotes H or an alkyl residue selected from the group consisting of —CH2—OH, —CH2—CH2—OH, —CH2—CH2—CH2—OH, —CH2—CH2—CH2—CH2—OH, isopropyl, n-butyl, sec.-butyl, isobutyl, tert-butyl, methyl, ethyl and n-propyl;
R7 denotes hydrogen or —OH; or
R6 and R7 together with the carbon atom to which they are attached form a residue selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl;
R8 denotes —SF5; —O—CF3; —O—CFH2; —O—CF2H; —CFH2; —CF2H; —CF3; or a tert.-butyl-residue, which may be unsubstituted or optionally substituted with 1, 2, 3, 4, 5, 6, 7, 8 or 9 substituents independently selected from the group consisting of F, Cl, Br, I, —CN, —NO2, —OH, —NH2, —SH, —O—CH3, —O—C2H5, —O—CH(CH3)2, —NH—CH3 and —NH—C2H5;
T denotes C—R35; U denotes C—R36; V denotes N, and W denotes C—R38; or
T denotes C—R35; U denotes N; V denotes C—R37, and W denotes C—R38; or
T denotes N; U denotes C—R36; V denotes C—R37, and W denotes C—R38; or
T denotes N; U denotes N; V denotes C—R37, and W denotes C—R38; or
T denotes N; U denotes C—R36; V denotes N, and W denotes C—R38; or
T denotes C—R35; U denotes N; V denotes N, and W denotes C—R38; or
T denotes C—R35; U denotes C—R36; V denotes C—R37, and W denotes C—R38;
R13, R14, R15, R16, R17, R26 and R27 each independently denote a residue selected from the group consisting of methyl, —CF3, —CCl3, —CBr3, —CHF2, —CH2F, —CF2Cl, —CCl2F, —CH2—CN, —CH2—O—CH3, —CH2—O—CF3, —CH2—SF3, ethyl, —CF2—CH3, —CH2—CF3, —C2F5, —CH2—CCl3, —CH2—CBr3, —CHF—CF2Cl, —CF2—CF2Cl, —CFCl—CF2Cl, —CH2—CH2—CN, n-propyl, —CF2—CF2—CF3, —CF(CF3)2, isopropyl, —CH2—CH2—CH2—CN, —CH2—O—CH2—CH3, —CH2—CH2—SF3, —CH2—CH2—OCF3, —CH(CH3)(O—CH3), —CH(CH3)(S—CH3), n-butyl, —CF2—CF2—CF2—CF3, —CH2—CH2—CH2—CH2—CN, sec.-butyl, isobutyl, tert.-butyl, n-pentyl, 3-pentyl, n-heptyl, 4-heptyl, n-octyl, n-nonyl, 5-nonyl, (2,6)-dimethyl-hept-4-yl, 3-methylbutyl, n-hexyl, (3,3)-dimethylbutyl, —CH2—CH2—O—CH3, —CH2—CH2—O—C2H5, —CH2—CH2—CH2—O—CH3, ethenyl, propenyl, 2-butenyl, 3-butenyl, 2-pentenyl and 3-pentenyl; or
a residue selected from the group consisting of 2,3-dihydro-1H-indenyl, cyclopropyl, oxetanyl, cyclobutyl, cyclopentyl, cyclohexyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, azepanyl, diazepanyl, azocanyl and thiomorpholinyl, which optionally may be attached via a —CH2—O, —CH2—CH2—O, —CH2—CH2—O—CH2, —CH2—CH(CH3)—O—CH2, —(CH2), —(CH2)2 or —(CH2)3 group, or which may be unsubstituted or optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of oxo (═O), thioxo (═S), —OH, —O—CH3, —O—C2H5, —O—CH(CH3)2, —O—C(CH3)3, —O—CF3, —S—CF3, —SH, —S—CH3, —S—C2H5, —S—CH(CH3)2, —S—C(CH3)3, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec.-butyl, isobutyl, tert.-butyl, n-pentyl, —C(═O)—CH3, —C(═O)—C2H5, —C(═O)—CH(CH3)2, —C(═O)—C(CH3)3, —C(═O)—OH, —C(═O)—O—CH3, —C(═O)—O—C2H5, —C(═O)—O—CH(CH3)2 and —C(═O)—O—C(CH3)3; or
a residue selected from the group consisting of phenyl, naphthyl, thiophenyl, furanyl, pyrrolyl, pyrazolyl, pyrazinyl, pyranyl, triazolyl, pyridinyl, imidazolyl, thiazolyl, oxazolyl and isoxazolyl, wherein said residue optionally may be attached via a —(CH2)—, —(CH2)2— or —(CH2)3— group, and wherein said residue may be unsubstituted or optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, I, —CN, —CF3, —SF5, —OH, —O—CH3, —O—C2H5, —O—CH(CH3)2, —O—C(CH3)3, —NH2, —NO2, —O—CF3, —S—CF3, —SH, —S—CH3, —S—C2H5, —S—CH(CH3)2, —S—C(CH3)3, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec.-butyl, isobutyl, tert.-butyl, n-pentyl, —C(═O)—OH, —C(═O)—O—CH3, —C(═O)—O—C2H5, —C(═O)—O—CH(CH3)2, —C(═O)—O—C(CH3)3, —NH—CH3, —NH—C2H5, —NH—C(CH3)3, —N(CH3)2, —N(C2H5)2, —N(CH3)(C2H5), —NH—C(═O)—O—CH3, —NH—C(═O)—O—C2H5, —NH—C(═O)—O—C(CH3)3, —C(═O)—H, —C(═O)—CH3, —C(═O)—C2H5, —C(═O)—CH(CH3)2, —C(═O)—C(CH3)3, —C(═O)—NH2, —C(═O)—NH—CH3, —C(═O)—NH—C2H5, —C(═O)—N(CH3)2, —C(═O)—N(C2H5)2, —O-phenyl, —O-benzyl, phenyl and benzyl;
R35, R36 and R37 each independently denote H; F; Cl; Br; I; —SF5; —NO2; —CN; —NH2; —OH; —SH; —C(═O)—NH2; —S(═O)2—NH2; —C(═O)—NH—OH; —C(═O)—OH; —C(═O)—H; —S(═O)2—OH; —NHR13; —NR14R15; —OR16; —SR17; —S(═O)—R25; —S(═O)2—R26; or a residue selected from the group consisting of —CH2—OH, methyl, —CF3, —CCl3, —CBr3, —CHF2, —CH2F, —CF2Cl, —CCl2F, ethyl, —CF2—CH3, —CH2—CF3, —C2F5, —CH2—CCl3, —CH2—CBr3, —CHF—CF2Cl, —CF2—CF2Cl, —CFCl—CF2Cl, n-propyl, —CF2—CF2—CF3, —CF(CF3)2, isopropyl, n-butyl, sec.-butyl, isobutyl and tert.-butyl; or
a phenyl residue, which may be unsubstituted or optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, I, —CN, —CF3, —SF5, —OH, —O—CH3, —O—C2H5, —O—CH(CH3)2, —O—C(CH3)3, —NH2, —NO2, —O—CF3, —S—CF3, —SH, —S—CH3, —S—C2H5, —S—CH(CH3)2, —S—C(CH3)3, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec.-butyl, isobutyl, tert.-butyl and n-pentyl;
R38 denotes —NR40R41; —OR42; or —SR43; or
a residue selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, azepanyl, diazepanyl, azocanyl and thiomorpholinyl, wherein said residue is attached via a carbon atom of the ring thereof or via a —(CH═CH), —C≡C or —C≡C—CH2 group to the parent structure, and wherein said residue may be unsubstituted or optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of —CN, —CH2—N(CH3)2, —CH2—N(C2H5)2, —CH2—NH—CH3, —CH2—NH—C2H5, —NC(═O)—C2H5]-phenyl, —NC(═O)—CH3]-phenyl, oxo (═O), thioxo (═S), —OH, —O—CH3, —O—C2H5, —O—CH(CH3)2, —O—C(CH3)3, —O—CF3, —S—CF3, —SH, —S—CH3, —S—C2H5, —S—CH(CH3)2, —S—C(CH3)3, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec.-butyl, isobutyl, tert.-butyl, n-pentyl, —C(═O)—CH3, —C(═O)—C2H5, —C(═O)—CH(CH3)2, —C(═O)—C(CH3)3, —C(═O)—OH, —C(═O)—O—CH3, —C(═O)—O—C2H5, —C(═O)—O—CH(CH3)2 and —C(═O)—O—C(CH3)3; or
a residue selected from the group consisting of (1,3)-benzodioxolyl, (1,4)-benzodioxanyl, tetrazolyl, (2,3)-dihydrothieno[3,4-b][1,4]dioxinyl, benzo[b]furanyl, phenyl, naphthyl, thiophenyl, furanyl, pyrrolyl, pyrazolyl, pyrazinyl, pyranyl, triazolyl, pyridinyl, imidazolyl, indolyl, isoindolyl, thiazolyl, oxazolyl, isoxazolyl, pyridazinyl, pyrazinyl, pyrimidinyl, indazolyl, quinoxalinyl, quinolinyl and isoquinolinyl, wherein said residue optionally may be attached via a —(CH═CH)—, —C≡C—, —(CH2)—, —(CH2)2— or —(CH2)3— group, and wherein said residue may be unsubstituted or optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, I, —CN, —CF3, —SF5, —OH, —O—CH3, —O—C2H5, —O—CH(CH3)2, —O—C(CH3)3, —NH2, —NO2, —O—CF3, —S—CF3, —SH, —S—CH3, —S—C2H5, —S—CH(CH3)2, —S—C(CH3)3, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec.-butyl, isobutyl, tert.-butyl, n-pentyl, —C(═O)—OH, —C(═O)—O—CH3, —C(═O)—O—C2H5, —C(═O)—O—CH(CH3)2, —C(═O)—O—C(CH3)3, —NH—CH3, —NH—C2H5, —NH—C(CH3)3, —N(CH3)2, —N(C2H5)2, —N(CH3)(C2H5), —NH—C(═O)—O—CH3, —NH—S(═O)2—CH3, —NH—S(═O2)—C2H5, —NH—S(═O)2—CH(CH3)2, —NH—C(═O)—O—C2H5, —NH—C(═O)—O—C(CH3)3, —C(═O)—H, —C(═O)—CH3, —C(═O)—C2H5, —C(═O)—CH(CH3)2, —C(═O)—C(CH3)3, —C(═O)—NH2, —C(═O)—NH—CH3, —C(═O)—NH—C2H5, —C(═O)—N(CH3)2, —C(═O)—N(C2H5)2, —O-phenyl, —O-benzyl, phenyl and benzyl;
R40, R41, R42, and R43, each independently denote a residue selected from the group consisting of methyl, —CF3, —CCl3, —CBr3, —CHF2, —CH2F, —CF2Cl, —CCl2F, —CH2—CN, —CH2—O—CH3, —CH2—O—CF3, —CH2—SF3, ethyl, —CF2—CH3, —CH2—CF3, —C2F5, —CH2—CCl3, —CH2—CBr3, —CHF—CF2Cl, —CF2—CF2Cl, —CFCl, —CF2Cl, —CH2—CH2—CN, n-propyl, —CF2—CF2—CF3, —CF(CF3)2, isopropyl, —CH2—CH2—CH2—CN, —CH2—O—CH2—CH3, —CH2—CH2—SF3, —CH2—CH2—OCF3, —CH(CH3)(O—CH3), —CH(CH3)(S—CH3), n-butyl, —CF2—CF2—CF2—CF3, —CH2—CH2—CH2—CH2—CN, sec.-butyl, isobutyl, tert.-butyl, n-pentyl, 3-pentyl, n-heptyl, 4-heptyl, n-octyl, n-nonyl, 5-nonyl, (2,6)-dimethyl-hept-4-yl, 3-methylbutyl, n-hexyl, (3,3)-dimethylbutyl, —CH2—CH2—O—CH3, —CH2—CH2—O—C2H5, —CH2—CH2—CH2—O—CH3, ethenyl, propenyl, 2-butenyl, 3-butenyl, 2-pentenyl and 3-pentenyl; or
a residue selected from the group consisting of 2,3-dihydro-1H-indenyl, cyclopropyl, oxetanyl, cyclobutyl, cyclopentyl, cyclohexyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, azepanyl, diazepanyl, azocanyl and thiomorpholinyl, which optionally may be attached via a —CH2—O—, —CH2—CH2—O—, —CH2—CH2—O—CH2, —CH2—CH(CH3)—O—CH2, —(CH2)—, —(CH2)2— or —(CH2)3— group, and which may be unsubstituted or optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of oxo (═O), thioxo (═S), —OH, —O—CH3, —O—C2H5, —O—CH(CH3)2, —O—C(CH3)3, —O—CF3, —S—CF3, —SH, —S—CH3, —S—C2H5, —S—CH(CH3)2, —S—C(CH3)3, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec.-butyl, isobutyl, tert.-butyl, n-pentyl, —C(═O)—CH3, —C(═O)—C2H5, —C(═O)—CH(CH3)2, —C(═O)—C(CH3)3, —C(═O)—OH, —C(═O)—O—CH3, —C(═O)—O—C2H5, —C(═O)—O—CH(CH3)2 and —C(═O)—O—C(CH3)3; or
a residue selected from the group consisting of phenyl, naphthyl, thiophenyl, furanyl, pyrrolyl, pyrazolyl, pyrazinyl, pyranyl, triazolyl, pyridinyl, imidazolyl, thiazolyl, oxazolyl and isoxazolyl, wherein said residue optionally may be attached via a —(CH2)—, —(CH2)2— or —(CH2)3— group, and wherein said residue may be unsubstituted or optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, I, —CN, —CF3, —SF5, —OH, —O—CH3, —O—C2H5, —O—CH(CH3)2, —O—C(CH3)3, —NH2, —NO2, —O—CF3, —S—CF3, —SH, —S—CH3, —S—C2H5, —S—CH(CH3)2, —S—C(CH3)3, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec.-butyl, isobutyl, tert.-butyl, n-pentyl, —C(═O)—OH, —C(═O)—O—CH3, —C(═O)—O—C2H5, —C(═O)—O—CH(CH3)2, —C(═O)—O—C(CH3)3, —NH—CH3, —NH—C2H5, —NH—C(CH3)3, —N(CH3)2, —N(C2H5)2, —N(CH3)(C2H5), —NH—C(═O)—O—CH3, —NH—C(═O)—O—C2H5, —NH—C(═O)—O—C(CH3)3, —C(═O)—H, —C(═O)—CH3, —C(═O)—C2H5, —C(═O)—CH(CH3)2, —C(═O)—C(CH3)3, —C(═O)—NH2, —C(═O)—NH—CH3, —C(═O)—NH—C2H5, —C(═O)—N(CH3)2, —C(═O)—N(C2H5)2, —O-phenyl, —O-benzyl, phenyl and benzyl; or
R40 and R41 together with the nitrogen atom to which they are attached form a residue selected from the group consisting of 3-aza-bicyclo[3.1.1]heptyl, 6-aza-spiro[2.5]octyl, 3-aza-bicyclo[3.2.1]octyl, 6-aza-bicyclo[3.3.1]heptyl, 8-aza-bicyclo[3.2.1]octyl, 1-oxa-2,8-diaza-spiro[4.5]dec-2-enyl, azocanyl, isoindolyl, indolyl, (1,2,3,6)-tetrahydropyridinyl, (4,5,6,7)-tetrahydroisoxazolo[5,4-c]pyridinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, azepanyl, diazepanyl and thiomorpholinyl, wherein the heterocycloaliphatic moiety may be unsubstituted or optionally substituted with 1, 2, 3, 4 or 5 residues R57;
R57 denotes —NHR58, —NR59R60; or an alkyl residue selected from the group consisting of —CF3, —CH2—CF3, methyl, ethyl, n-propyl, isopropyl, tert.-butyl, n-butyl, sec.-butyl, and isobutyl;
R58, R59 and R60 each independently denote —C(═O)—R61; or an alkyl residue selected from the group consisting of —CF3, —CH2—CF3, methyl, ethyl, n-propyl, isopropyl, tert.-butyl, n-butyl, sec.-butyl, and isobutyl; or
a residue selected from the group consisting of phenyl, naphthyl, thiophenyl, furanyl, pyrrolyl, pyrazolyl, pyrazinyl, pyranyl, triazolyl, pyridinyl, imidazolyl, thiazolyl, oxazolyl and isoxazolyl, wherein said residue optionally may be attached via a —(CH2)—, —(CH2)2— or —(CH2)3— group, and may be unsubstituted or optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, I, —CN, —CF3, —SF5, —OH, —O—CH3, —O—C2H5, —O—CH(CH3)2, —O—C(CH3)3, —NH2, —NO2, —O—CF3, —S—CF3, —SH, —S—CH3, —S—C2H5, —S—CH(CH3)2, —S—C(CH3)3, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec.-butyl, isobutyl, tert.-butyl, n-pentyl, —C(═O)—OH, —C(═O)—O—CH3, —C(═O)—O—C2H5, —C(═O)—O—CH(CH3)2, —C(═O)—O—C(CH3)3, —NH—CH3, —NH—C2H5, —NH—C(CH3)3, —N(CH3)2, —N(C2H5)2, —N(CH3)(C2H5), —NH—C(═O)—O—CH3, —NH—C(═O)—O—C2H5, —NH—C(═O)—O—C(CH3)3, —C(═O)—H, —C(═O)—CH3, —C(═O)—C2H5, —C(═O)—CH(CH3)2, —C(═O)—C(CH3)3, —C(═O)—NH2, —C(═O)—NH—CH3, —C(═O)—NH—C2H5, —C(═O)—N(CH3)2, —C(═O)—N(C2H5)2, —O-phenyl, —O-benzyl, phenyl and benzyl; and
R61 denotes an alkyl residue selected from the group consisting of —CF3, —CH2—CF3, methyl, ethyl, n-propyl, isopropyl, tert.-butyl, n-butyl, sec.-butyl and isobutyl;
or a salt thereof.

### Claim 6 (depends on 1)

A compound according to claim 1, wherein:
n is 0, 1 or 2;
R1 and R2 together denote —CH═CH—N═CH—, which may be attached in any desired direction to the parent structure; or
R2 and R3 together denote a residue selected from the group consisting of —CH═CH—CH═N— and —CH═CH—N═CH— which may be attached in any desired direction to the parent structure; or
R3 and R4 together denote a residue selected from the group consisting of —CH═CH—CH═N— and —CH═CH—N═CH—, which may be attached in any desired direction to the parent structure; or
R4 and R5 together denote —CH═CH—N═CH—, which is attached in any desired direction to the parent structure, and
the remaining residues of R1, R2, R3, R4 and R5 each independently denote H; F; Cl; Br; I; —CF3; —CN; —OR16; —SR17; or denote a residue selected from the group consisting of methyl, —CF3, —CHF2, —CH2F, ethyl, n-propyl, isopropyl, n-butyl, sec.-butyl, isobutyl and tert.-butyl;
R6 denotes H or an alkyl residue selected from the group consisting of isopropyl, n-butyl, sec.-butyl, isobutyl, tert-butyl, methyl, ethyl and n-propyl;
R7 denotes hydrogen or —OH; or
R6 and R7 together with the carbon atom to which they are attached form a residue selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl;
R8 denotes —SF5; —O—CF3; —CF3; tert.-butyl, or —C(CH3)2 (CH2OH);
T denotes C—R35; U denotes C—R36V denotes N, and W denotes C—R38; or
T denotes C—R35; U denotes C—R36; V denotes C—R37, and W denotes C—R38;
R16 and R17 each independently denote a residue selected from the group consisting of methyl, —CF3, —CHF2, —CH2F, ethyl, —CF2—CH3, —CH2—CF3, —C2F5, n-propyl, isopropyl, n-butyl, sec.-butyl, isobutyl, tert.-butyl, n-pentyl, 3-pentyl, n-heptyl, 4-heptyl, n-octyl, n-nonyl, 5-nonyl, (2,6)-dimethyl-hept-4-yl, 3-methylbutyl, n-hexyl and (3,3)-dimethylbutyl;
R35, R36 and R37 each independently denote H; F; Cl; Br; I; —SF5; —NO2; —CN; —NH2; —OH; —SH; —OR16; —SR17; or a residue selected from the group consisting of —CH2—OH, methyl, —CF3, —CHF2, —CH2F, ethyl, n-propyl, isopropyl, n-butyl, sec.-butyl, isobutyl and tert.-butyl;
R38 denotes —NR40R41; —OR42; —SR43; or a residue selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, azepanyl, diazepanyl, azocanyl and thiomorpholinyl, wherein said residue is attached via a carbon atom of the ring thereof to the parent structure, and wherein said residue may be unsubstituted or optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of —CH2—N(CH3)2, —CH2—N(C2H5)2, —CH2—NH—CH3, —CH2—NH—C2H5, —NC(═O)—C2H5]-phenyl, —NC(═O)—CH3]-phenyl, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec.-butyl, isobutyl and tert.-butyl; or
a residue selected from the group consisting of phenyl, thiophenyl, furanyl, pyrrolyl, pyrazolyl, pyrazinyl, pyranyl, triazolyl, pyridinyl, imidazolyl, thiazolyl, oxazolyl, isoxazolyl, pyridazinyl, pyrazinyl and pyrimidinyl, wherein said residue optionally may be substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, I, —CN, —CF3, —SF5, —OH, —O—CH3, —O—C2H5, —O—CH(CH3)2, —O—C(CH3)3, —O—CF3, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec.-butyl, isobutyl, tert.-butyl and n-pentyl;
R40, R41, R42 and R43 each independently denote a residue selected from the group consisting of methyl, —CH2—O—CH3, ethyl, n-propyl, isopropyl, n-butyl, sec.-butyl, isobutyl, tert.-butyl, n-pentyl, 3-pentyl, n-hexyl, (3,3)-dimethylbutyl, —CH2—CH2—O—CH3, —CH2—CH2—O—C2H5 and —CH2—CH2—CH2—O—CH3; or
a residue selected from the group consisting of 2,3-dihydro-1H-indenyl, cyclopropyl, oxetanyl, cyclobutyl, cyclopentyl, cyclohexyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, azepanyl, diazepanyl, azocanyl and thiomorpholinyl, wherein said residue optionally may be substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec.-butyl, isobutyl, tert.-butyl, n-pentyl; or
R40 and R41 together with the nitrogen atom to which they are attached form a residue selected from the group consisting of 3-aza-bicyclo[3.1.1]heptyl, 6-aza-spiro[2.5]octyl, 3-aza-bicyclo[3.2.1]octyl, 6-aza-bicyclo[3.3.1]heptyl, 8-aza-bicyclo[3.2.1]octyl, 1-oxa-2,8-diaza-spiro[4.5]dec-2-enyl, azocanyl, isoindolyl, indolyl, (1,2,3,6)-tetrahydropyridinyl, (4,5,6,7)-tetrahydroisoxazolo[5,4-c]pyridinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, azepanyl, diazepanyl and thiomorpholinyl, wherein the heterocycloaliphatic moiety of said residue may be unsubstituted or optionally substituted with 1, 2, 3, 4 or 5 residues R57;
R57 denotes —NHR58, —NR59R60; or an alkyl residue selected from the group consisting of —CF3, —CH2—CF3, methyl, ethyl, n-propyl, isopropyl, tert.-butyl, n-butyl, sec.-butyl, and isobutyl;
R58, R59 and R60 each independently denote —C(═O)—R61; or an alkyl residue selected from the group consisting of —CF3, —CH2—CF3, methyl, ethyl, n-propyl, isopropyl, tert.-butyl, n-butyl, sec.-butyl, and isobutyl; or
a residue selected from the group consisting of phenyl and naphthyl, wherein said residue optionally may be attached via a —(CH2)—, —(CH2)2— or —(CH2)3 group, and wherein said residue may be unsubstituted or optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, I, —CN, —CF3, —O—CH3, —O—C2H5, —O—CH(CH3)2, —O—C(CH3)3, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec.-butyl, isobutyl, tert.-butyl and n-pentyl; and
R61 denotes an alkyl residue selected from the group consisting of —CF3, —CH2—CF3, methyl, ethyl, n-propyl, isopropyl, tert.-butyl, n-butyl, sec.-butyl and isobutyl;
or a salt thereof.

### Claim 7 (depends on 1)

A compound according to claim 1, wherein:
n is 0, 1 or 2;
R1 and R2 together denote —CH═CH—N═CH—, which is attached in any desired direction to the parent structure; or
R2 and R3 together denote a residue selected from the group consisting of —CH═CH—CH═N— and —CH═CH—N═CH—, which is attached in any desired direction to the parent structure; or
R3 and R4 together denote a residue selected from the group consisting of —CH═CH—CH═N— and —CH═CH—N═CH—, which is attached in any desired direction to the parent structure; or
R4 and R5 together denote —CH═CH—N═CH—, which is attached in any desired direction to the parent structure; and
the remaining residues of R1, R2, R3, R4 and R5 each independently denote H; —OR16; —SR17; or a residue selected from the group consisting of methyl, —CF3, —CHF2, —CH2F, ethyl, n-propyl, isopropyl, n-butyl, sec.-butyl, isobutyl and tert.-butyl;
R6 denotes H or an alkyl residue selected from the group consisting of isopropyl, n-butyl, sec.-butyl, isobutyl, tert-butyl, methyl, ethyl and n-propyl;
R7 denotes hydrogen or —OH;
R8 denotes —SF5; —O—CF3; —CF3; tert.-butyl, or —C(CH3)2(CH2OH);
T denotes C—R35; U denotes C—R36; V denotes N, and W denotes C—R38; or
T denotes C—R35; U denotes C—R36; V denotes C—R37, and W denotes C—R38;
R16 and R17 each independently denote a residue selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec.-butyl, isobutyl, tert.-butyl, and n-pentyl;
R35, R36 and R37 each denote H;
R38 denotes —NR40R41; —OR42; or —SR43;
R42 and R43 each independently denote a residue selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec.-butyl, isobutyl, tert.-butyl, n-pentyl, 3-pentyl, n-hexyl, and (3,3)-dimethylbutyl; or
a residue selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl, which optionally may be substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec.-butyl, isobutyl, tert.-butyl, and n-pentyl; or
R40 and R41 together with the nitrogen atom to which they are attached form a residue selected from the group consisting of pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl and azepanyl, wherein the heterocycloaliphatic moiety may be unsubstituted or optionally substituted with 1, 2, 3, 4 or 5 residues R57; and
R57 denotes an alkyl residue selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, tert.-butyl, n-butyl, sec.-butyl, and isobutyl;
or a salt thereof.

### Claim 8 (depends on 1)

A compound according to claim 1, wherein:
n is 1;
R1 and R2 together denote —CH═CH—N═CH—, which is attached in any desired direction to the parent structure; or
R2 and R3 together denote a residue selected from the group consisting of —CH═CH—CH═N— and —CH═CH—N═CH—, which is attached in any desired direction to the parent structure; or
R3 and R4 together denote a residue selected from the group consisting of —CH═CH—CH═N— and —CH═CH—N═CH—, which is attached in any desired direction to the parent structure; or
R4 and R5 together denote —CH═CH—N═CH—, which is attached in any desired direction to the parent structure, and
the remaining residues of R1, R2, R3, R4 and R5 each independently denote H; —OR16; —SR17; or a residue selected from the group consisting of methyl, —CF3, —CHF2, —CH2F, ethyl, n-propyl, isopropyl, n-butyl, sec.-butyl, isobutyl and tert.-butyl;
R6 denotes H or an alkyl residue selected from the group consisting of isopropyl, n-butyl, sec.-butyl, isobutyl, tert-butyl, methyl, ethyl and n-propyl;
R7 denotes hydrogen or —OH;
R8 denotes —SF5; —O—CF3; —CF3; tert.-butyl, or —C(CH3)2(CH2OH);
T denotes C—R35; U denotes C—R36V denotes N, and W denotes C—R38; or
T denotes C—R35; U denotes C—R36; V denotes C—R37, and W denotes C—R38;
R16 and R17 each independently denote a residue selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec.-butyl, isobutyl, tert.-butyl, and n-pentyl;
R35, R36 and R37 each denote H;
R38 denotes —NR40R41; —OR42; —SR43;
R42 and R43 each independently denote a residue selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec.-butyl, isobutyl, tert.-butyl, n-pentyl, 3-pentyl, n-hexyl, and (3,3)-dimethylbutyl; or
a cycloalkyl residue selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl, which optionally may be substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec.-butyl, isobutyl, tert.-butyl, n-pentyl; or
R40 and R41 together with the nitrogen atom to which they are attached form a residue selected from the group consisting of pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl and azepanyl, wherein the heterocycloaliphatic moiety may be unsubstituted or optionally substituted with 1, 2, 3, 4 or 5 residues R57; and
R57 denotes an alkyl residue selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, tert.-butyl, n-butyl, sec.-butyl, and isobutyl;
or a salt thereof.

### Claim 9 (depends on 6)

A compound according to claim 6, corresponding to formula Ib:
wherein
D denotes N or CH; and
R1, R2, R3, R4, R5, R8 and R42 have the respective meanings given in claim 6;
or a salt thereof.

### Claim 10 (depends on 7)

A compound according to claim 7, corresponding to formula Ib:
wherein
D denotes N or CH; and
R1, R2, R3, R4, R5, R8 and R42 have the respective meanings given in claim 7;
or a salt thereof.

### Claim 11 (depends on 6)

A compound according to claim 6, corresponding to formula Ic:
wherein
D denotes N or CH; and
R1, R2, R3, R4, R5, R8 and R43 have the respective meanings given in claim 6;
or a salt thereof.

### Claim 12 (depends on 7)

A compound according to claim 7, corresponding to formula Ic:
wherein
D denotes N or CH; and
R1, R2, R3, R4, R5, R8 and R43 have the respective meanings given in claim 7;
or a salt thereof.

### Claim 13 (depends on 6)

A compound according to claim 6, corresponding to formula Id:
wherein
D denotes N or CH; and
R1, R2, R3, R4, R5, R8, R40 and R41 have the respective meanings given in claim 6;
or a salt thereof.

### Claim 14 (depends on 7)

A compound according to claim 7, corresponding to formula Id:
wherein
D denotes N or CH; and
R1, R2, R3, R4, R5, R8, R40 and R41 have the respective meanings given in claim 7;
or a salt thereof.

### Claim 15 (depends on 1)

A compound according to claim 1, selected from the group consisting of:
[64] 2-(Isoquinolin-7-yl)-N-((2-(4-methylpiperidin-1-yl)-6-(trifluormethyl)pyridin-3-yl)-methyl)propanamide;
[65] 2-(isoquinolin-6-yl)-N-((2-(4-methylpiperidin-1-yl)-6-(trifluoromethyl)pyridin-3-yl)-methyl)propanamide; and
[66] N-((2-(4-methylpiperidin-1-yl)-6-(trifluoromethyl)pyridin-3-yl)methyl)-2-(quinoline-6-yl)propanamide;
or a salt thereof.

### Claim 16 (depends on 1)

A compound according to claim 1, wherein, in a FLIPR assay with CHO K1 cells transfected with a human gene VR1, said compound in a concentration of less than 2000 nM, causes a 50% displacement of capsaicin which is present in a concentration of 100 nM.

### Claim 17 (depends on 16)

A compound according to claim 16, wherein said compound in a concentration of less then 300 nM, causes a 50% displacement of capsaicin which is present in a concentration of 100 nM.

### Claim 18 (depends on 17)

A compound according to claim 17, wherein said compound in a concentration of less then 75 nM, causes a 50% displacement of capsaicin which is present in a concentration of 100 nM.

### Claim 19 (depends on 18)

A compound according to claim 18, wherein said compound in a concentration of less then 10 nM, causes a 50% displacement of capsaicin which is present in a concentration of 100 nM.

### Claim 20 (depends on 1)

A pharmaceutical composition comprising a compound according to claim 1 and at least one pharmaceutically acceptable carrier or adjuvant.

### Claim 21 (depends on 1)

A process for producing a compound according to claim 1, said process comprising:
reacting a compound corresponding to formula II:
wherein
R8, U, T, V, and W have the respective meanings given in claim 1;
m is 0, 1, 2 or 3, and
R denotes hydrogen or a linear or branched C1-6 alkyl residue,
in a reaction medium, in the presence of a reducing agent,
to yield a compound corresponding to formula III:
wherein R8, U, T, V, W and m have the respective meanings given above, and optionally isolating or purifying said compound of formula III;
reacting the compound corresponding to formula III, in a reaction medium, in the presence of diphenylphosphoryl azide or of HN3
to yield a compound corresponding to formula IV:
wherein R8, U, T, V, W and m have the respective meanings given above, and optionally isolating or purifying said compound of formula IV;
reacting a compound corresponding to formula IV,
in a reaction medium in the presence of a reducing agent, or
in a reaction medium in the presence of a catalyst and of hydrogen or hydrazine, or
in a reaction medium in the presence of triphenylphosphine,
to yield a compound corresponding to formula V:
wherein R8, U, T, V, W and m have the respective meanings given above;
and optionally isolating or purifying said compound of formula V;
or
reacting a compound corresponding to formula VI:
wherein R8, U, T, V, W and m have the respective meanings given above,
in a reaction medium and in the presence of at least one catalyst under a hydrogen atmosphere, optionally in the presence of an acid; or
in the presence of a reducing agent selected from the group consisting of BH3.S(CH3)2, lithium aluminium hydride and sodium borohydride, and optionally in the presence of NiCl2,
to yield a compound corresponding to formula V or a salt thereof,
and optionally isolating or purifying said compound of formula V or salt thereof; and
reacting the compound corresponding to formula V
with a compound corresponding to formula VII:
wherein R1, R2, R3, R4, R5, R6 and R7 have the respective meanings given in claim 1,
in a reaction medium, optionally in the presence of a coupling agent and optionally in the presence of a base, or
with a compound corresponding to formula VIII:
wherein R1, R2, R3, R4, R5, R6 and R7 have the respective meanings given above, and LG denotes a leaving group,
in a reaction medium, optionally in the presence of a base,
to yield a compound corresponding to formula I:
wherein T, U, V, W, R1, R2, R3, R4, R5, R6, R7 and R8 have the respective meanings given above, and n is 1, 2, 3 or 4,
and optionally isolating or purifying the compound of formula I.

### Claim 22 (depends on 21)

A process according to claim 21, wherein:
said compound of formula II is reacted in the presence of a reducing agent selected from the group consisting of sodium hydride, sodium, potassium hydride, lithium aluminium hydride, sodium borohydride and di(isobutyl)aluminium hydride; or
said compound of formula IV is reacted in the presence of a reducing agent selected from the group consisting of sodium hydride, potassium hydride, lithium aluminium hydride, sodium borohydride and di(isobutyl)aluminium hydride; or
said compound of formula IV is reacted in the presence of a platinum or palladium catalyst; or
said compound of formula VI is reacted in the presence of a palladium or platinum catalyst; or
said compound of formula VI is reacted in the presence of hydrochloric acid; or
LG denotes a chlorine or bromine atom.

### Claim 23 (depends on 1)

A process for producing a compound according to claim 1, said process comprising:
reacting a compound corresponding to formula X:
wherein
R8, U, T, V, and W have the respective meanings given in claim 1,
with a compound corresponding to formula VII:
wherein R1, R2, R3, R4, R5, R6 and R7 have the respective meanings given in claim 1,
in a reaction medium, and optionally in the presence of a coupling agent, and optionally in the presence of a base,
or
with a compound corresponding to formula VIII:
wherein R1, R2, R3, R4, R5, R6 and R7 have the respective meanings given above, and LG denotes a leaving group,
in a reaction medium, and optionally in the presence of a base,
to yield a compound corresponding to formula Im:
wherein T, U, V, W, R1, R2, R3, R4, R5, R6, R7 and R8 have the respective meanings given above,
and optionally isolating or purifying the compound of formula Im.

### Claim 24 (depends on 1)

A method of treating pain in a subject, said method comprising administering to said subject a pharmacologically effective amount of a compound according to claim 1, wherein said pain is selected from the group consisting of acute pain, chronic pain, neuropathic pain, visceral pain, joint pain, hyperalgesia, allodynia, causalgia and migraine.